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Abstract
 
Human hematopoietic tissue contains rare stem cells with multilineage reconstituting ability
demonstrable in receptive xenogeneic hosts. We now show that within 3 wk nonobese dia-
betic severe combined immunodeficiency (NOD/SCID) mice transplanted with human fetal
liver cells regenerate near maximum levels of daughter human hematopoietic stem cells (HSCs)
able to repopulate secondary NOD/SCID mice. At this time, most of the human HSCs (and
other primitive progenitors) are actively proliferating as shown by their sensitivity to treatments
that kill cycling cells selectively (e.g., exposure to high specific-activity [
 
3
 
H]thymidine in vitro
or 5-fluorouracil in vivo). Interestingly, the proliferating human HSCs were rapidly forced into
quiescence by in vivo administration of stromal-derived factor-1 (SDF-1) and this was accom-
panied by a marked increase in the numbers of human HSCs detectable. A similar result was
obtained when transforming growth factor-
 
 
 
 was injected, consistent with a reversible change
in HSCs engrafting potential linked to changes in their cell cycle status. By 12 wk after trans-
plant, most of the human HSCs had already entered G
 
o
 
 and treatment with SDF-1 had no effect
on their engrafting activity. These findings point to the existence of novel mechanisms by
which inhibitors of HSC cycling can regulate the engrafting ability of human HSCs executing
self-renewal divisions in vivo.
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Introduction
 
In the last decade, major advances have been made in the
functional characterization of human hematopoietic stem
cells (HSCs).
 
*
 
 Key to this progress has been the discovery
that these cells (even at limiting dilutions) can generate
multiple types of differentiating progeny for prolonged pe-
riods of time, both in stromal-based culture systems (1–5)
and in immunodeficient xenogeneic recipients (6–10).
Sublethally irradiated nonobese diabetic (NOD)/SCID
mice are particularly useful hosts for in vivo studies of hu-
man HSCs because of the efficiency (11), selectivity (12),
and speed (7, 13) with which these mice are repopulated
with the lymphoid and myeloid progeny of a very primi-
tive subset of transplantable human cells. It has thus be-
come practical to measure and resolve differences in human
HSC frequencies in variously manipulated populations us-
ing relatively short term endpoints of human multilineage
repopulation of NOD/SCID mice (8, 14). During the ini-
tial 4–6 wk after transplantation of human HSCs into pri-
mary NOD/SCID mice, the number of human cells able
to produce both lymphoid and myeloid progeny in sec-
ondary NOD/SCID mice also rapidly increases (14–16).
This finding suggests that at least some of the human
HSCs that produce differentiating lymphoid and myeloid
cells after injection into NOD/SCID mice also generate
daughter HSCs that can be detected by injection into sec-
ondary NOD/SCID mice. More recent analyses of sec-
ondary recipients of retrovirally marked human HSCs pro-
vide further support for this view (17). However, little is
known about the factors that control human HSC cycling
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ture-initiating cell; NOD, nonobese diabetic; PI, propidium iodide;
SDF-1, stromal-derived factor 1. 
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in vivo or whether these may be active in engrafted
NOD/SCID mice.
The present studies were designed to address these ques-
tions in NOD/SCID recipients of human fetal liver cells.
This source of human HSCs was chosen because of the
high HSC content in fetal liver and the ability of fetal liver
HSCs to readily amplify their numbers in this model. Two
complementary approaches were used to assess the prolifer-
ative activity of the regenerated human HSCs. The first re-
lied on the ability of high specific activity [
 
3
 
H]thymidine to
deliver a lethal dose of radiation exclusively to cells passing
through S-phase (18) and the use of a sufficiently pro-
longed exposure time to allow all HSCs in G
 
1
 
, G
 
2
 
, or M to
also enter S-phase (19). As a result, only HSCs in G
 
o
 
 would
not be killed by this treatment. The second approach ex-
ploited the ability of in vivo administered 5-fluorouracil (5-
FU) to kill proliferating hematopoietic cells selectively but
by a different mechanism (20). Because it had been shown
that HSCs undergo marked but reversible fluctuations in
their engraftment activity as they transit the cell cycle (21–
23) we hypothesized that treatment of primary NOD/
SCID hosts with agents able to arrest human HSC cycling
would cause an apparent increase in the number of human
HSCs detected in secondary recipients if, and only if, the
HSCs in the primary hosts were proliferating. Both TGF-
 
 
 
and stromal-derived factor 1 (SDF-1) have been found to
inhibit the cycling of primitive human progenitors detect-
able in vitro, including cells able to sustain hematopoiesis
for at least 6 wk in stroma-containing cultures (24–26). Ev-
idence that TGF-
 
 
 
 can block the cell cycle entry of trans-
plantable human HSCs has also been reported (27). Ac-
cordingly, 3 wk after transplant, we injected primary
recipients of human fetal liver cells with either TGF-
 
 
 
 or
SDF-1 and then looked for effects on the subsequent re-
populating activity detected upon transfer of the treated
cells to secondary NOD/SCID recipients.
 
Materials and Methods
 
Human Cell Preparation.
 
Fetal livers obtained from 12 to 16
wk aborted fetuses according to approved institutional procedures
were suspended using dispase (Dispase II; Sigma-Aldrich) and
DNase (DNase I; Sigma-Aldrich) as described previously (28).
Low-density (
 
 
 
1.077 g/ml) cells were isolated using Ficoll/
Hypaque (Amersham Biosciences) and then cryopreserved in
DMSO plus 90% FCS (StemCell Technologies Inc.).
 
Animals.
 
NOD/LtSz-
 
scid/scid
 
 mice were bred and main-
tained in the animal facility of the British Columbia Cancer Re-
search Centre (Vancouver, BC, Canada) under microisolators
and were provided with sterilized food and water. After being ir-
radiated, mice were given acidified water containing ciprofloxa-
cin (100 mg/l; Bayer AG). Mice were irradiated with 350 cGy
 
137
 
Cs 
 
 
 
-rays at 6 to 8 wk of age and then injected intravenously
with 10
 
7
 
 freshly thawed low-density human fetal liver cells. Pri-
mary mice were killed and analyzed for the presence of human
cells and progenitors either 2 1/2 to 3, or 12 wk later, as indi-
cated. In some experiments, groups of mice were injected intra-
venously with either 150 mg/kg 5-FU (Faulding) or PBS 2 d be-
fore being killed. In others, groups of primary mice were injected
 
intraperitoneally twice, 24 h apart, with PBS containing either 1
 
 
 
g TGF-
 
 
 
1
 
 (R&D Systems), or 10 
 
 
 
g SDF-1 (synthesized and
purified as described [29]) or no other agent, 1 or in some cases
3 d before being killed. Secondary recipients were irradiated in
the same way as primary mice and injected intravenously with
equal proportions of marrow cells harvested from primary mice.
All secondary recipients were killed 6 to 8 wk after transplant and
their marrow cells were then analyzed for the presence of human
cells by FACS
 
®
 
 as described below.
 
Flow Cytometry and Calculation of Human HSC Numbers.
 
The
procedure used to detect human cells in suspensions harvested
from transplanted mice has been outlined in detail previously (14,
25). Briefly, red cells were lysed with 8.3% ammonium chloride,
the nucleated cells then counted, washed in Hanks Balanced Salt
Solution with 2% FCS, and incubated with human serum and 3
 
 
 
g/ml of an anti–mouse IgG receptor antibody to minimize
nonspecific staining. One aliquot was then stained with anti–
human CD34-FITC and anti–human CD19-PE and CD20-PE
(Becton Dickinson) with propidium iodide (PI; Sigma-Aldrich)
added to the last wash to permit the identification of viable (PI
 
 
 
)
human progenitor (CD34
 
 
 
) and exclusively B-lineage (CD34
 
 
 
CD19/20
 
 
 
) populations. A second aliquot was stained with anti-
human CD45-PE (Hlel; Becton Dickinson), CD71-PE (OKT-
9), CD15-FITC, and CD66b-FITC and PI to quantify the total
viable human hematopoietic (CD45/71
 
 
 
) cell population present
as well as a subset of exclusively granulopoietic (CD15/66b
 
 
 
)
cells within this population. Additional aliquots were stained with
irrelevant antibodies labeled with PE or FITC to set gates for pos-
itive staining based on exclusion of 99.99% of events seen in these
controls. LYSIS II software (Becton Dickinson) was used for ac-
quisition and analysis of FACS
 
®
 
 data. For each analysis a mini-
mum of 2 
 
 
 
 10
 
4
 
 viable (PI
 
 
 
) cells were assessed and only when
 
 
 
5 positive events were recorded (for each gate setting) was the
value used to quantitate a specific human cell phenotype. The
frequency of human HSCs present in a given test cell suspension
was calculated using the L-calc software (StemCell Technologies,
Inc.) as described for cells referred to as competitive repopulating
units (CRUs) from the proportions of negative mice detected in
groups given different doses of test cells, where the definition of a
negative mouse was one that was not positive for both human
myeloid and human B-lineage cells (14). To calculate the total
number of human HSCs present in the marrow of primary mice,
it was assumed that two femurs and two tibias contained 25% of
all the marrow cells in a mouse (30).
 
In Vitro Progenitor Assays.
 
Human colony-forming cells (CFCs)
were enumerated in marrow cell suspensions harvested from mice
by plating the cells in methylcellulose cultures that incorporated
conditions that minimize the simultaneous detection of murine
CFCs (7). Human long-term culture-initiating cells (LTC-ICs)
were measured by coculturing aliquots of the same cell suspen-
sions with murine feeders engineered to produce human Steel
factor (SF), IL-3, and G-CSF for 6 wk at 37
 
 
 
C as described previ-
ously (3) and then counting the number of colonies obtained
when the cells harvested from these cultures were plated in CFC
assays that are selective for human cells. Erythroid CFCs (burst
forming erythroids [BFU-Es]) and granulopoietic CFCs (CFU-
GMs) were subdivided into primitive and mature categories based
on their ability to generate large and small colonies using well es-
tablished criteria (31).
 
[
 
3
 
H]Thymidine Suicide Experiments.
 
Marrow cells harvested
from primary mice were depleted of red cells by ammonium
chloride lysis, washed in PBS, resuspended in Iscove’s medium
containing a serum substitute (BIT™; StemCell Technologies, 
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Inc.) supplemented with 10
 
 
 
4
 
 2-mercaptoethanol (Sigma-Aldrich),
40 
 
 
 
g/ml high density lipoproteins (Sigma-Aldrich) and recom-
binant human SF (100 ng/ml, prepared and purified in the Terry
Fox Laboratory), IL-3 (20 ng/ml; Novartis), and G-CSF (20 ng/
ml; StemCell Technologies), and incubated at 2 
 
 
 
 10
 
6
 
 cells/ml
for 16 h with or without high specific activity [
 
3
 
H]thymidine (20
 
 
 
Ci/ml, 25 Ci/mmol; Amersham Biosciences) as described pre-
viously (19). The cells were then washed and assayed by plating
suitable aliquots in CFC or LTC-IC assay cultures or by injecting
suitable aliquots into irradiated NOD/SCID mice.
 
Results
 
Most of the Human HSCs Present in NOD/SCID Mice In-
jected 3 wk previously with Human Fetal Liver Cells Are Cy-
cling.
 
Previous experiments have described the rapid re-
generation of human hematopoietic cells, including CFCs
and LTC-ICs that occurs in the marrow of sublethally irra-
diated NOD/SCID mice transplanted with 10
 
7
 
 low-den-
sity human fetal liver cells (13). During the first 2 wk after
transplant, the number of all of these cell types increases
100 to 1,000-fold followed in the next 2 wk by a slower
pace of expansion with peak values being achieved at the
end of that time. Secondary transplant studies have demon-
strated that by 4 wk after transplant, the marrow of such
primary mice contains many more transplantable human
HSCs than were initially injected (11, 14). Therefore, we
chose the 3 wk posttransplant time to look for evidence of
human HSC proliferation in this model.
Fig. 1 shows the combined results of a first series of
three experiments in which cells harvested from the mar-
row of primary NOD/SCID mice injected with 10
 
7
 
 low-
density human fetal liver cells 3 wk previously were incu-
bated overnight in the presence or absence of high specific
activity [
 
3
 
H]thymidine before being assayed for their abil-
ity to repopulate secondary NOD/SCID mice. It can be
seen that 15 of the 16 secondary recipients of control cells
showed multilineage engraftment (
 
 
 
5 CD34
 
 
 
CD19/20
 
 
 
and 
 
 
 
5 CD45
 
 
 
CD15/66b
 
 
 
 cells per 2 
 
 
 
 10
 
4
 
 viable cells
analyzed [14]). In contrast, this was true for only 3 of the
15 secondary recipients of identical aliquots of initial cells
that had been exposed to [
 
3
 
H]thymidine. When Poisson
statistics were used to calculate the frequency of trans-
plantable human multilineage HSCs detectable in each
group as described in Materials and Methods, a 13-fold
lower value was obtained for the [
 
3
 
H]thymidine-treated
HSCs. Thus, a majority of the human HSCs from the pri-
mary mice must have entered S-phase at some point dur-
ing the 16 h period of exposure to [
 
3
 
H]thymidine in vitro
resulting in a 93% kill value. This indicates that 
 
 
 
90% of
the human HSCs present in the 3-wk engrafted mice were
proliferating, and conversely, that 
 
 
 
10% were in G
 
o.
 
 Sim-
ilar results were obtained for the human CFCs and LTC-
ICs present in the same cell suspensions (unpublished data,
but see also controls in Fig. 4, discussed below and previ-
ous studies [7, 25]).
In a second series of eight experiments, the cycling activ-
ity of the human HSCs present in such 3-wk posttransplant
mice was assessed by measuring their numbers 2 d after be-
ing injected (or not) with 150 mg/kg 5-FU. The numbers
of human HSCs detectable in the untreated and 5-FU–
treated primary mice were calculated from the frequencies
of negative secondary recipients of equal aliquots of mar-
row from the two types of primary mice and the values ob-
tained are shown in the left part of Fig. 2. It can be seen
that at 3 wk after transplant, 5-FU treatment reduced the
human HSC population in the primary mice by a factor of
 
 
 
30 (29 negative secondary mice of 29 injected with cells
from 5-FU–treated primary mice versus 11 negative sec-
Figure 1. [3H]Thymidine cell
suicide assays show most of the
human HSCs present in NOD/
SCID mice transplanted 3 wk be-
fore with human fetal liver cells
are cycling. Marrow cells were re-
moved from both femurs and tib-
ias of primary NOD/SCID recip-
ients of 107 low-density human
fetal liver cells transplanted 18 to
21 d previously (12 to 20 mice per
experiment, three experiments),
pooled, and exposed to [3H]thy-
midine (or not) for 16 h in vitro
before being injected into second-
ary NOD/SCID mice (equal ali-
quots of 0.56–0.88 primary mouse
marrow equivalents per secondary
mouse). Each symbol indicates the
number of human cells of the
phenotype indicated measured in
the same four hind leg bones of
individual secondary recipients of
control (open symbols) or [3H]thy-
midine-treated primary bone
marrow cells (solid symbols) as-
sessed 6 to 8 wk later. 
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ondary mice of 29 injected with control cells). 5-FU treat-
ment also decreased significantly (P 
 
 
 
 .05) the numbers of
other types of human progenitors assayed in the same ex-
periments (Table I).
 
The Population of Human HSCs Regenerated in Human Fe-
tal Liver-engrafted NOD/SCID Mice Is Sustained Over Time
but Becomes Quiescent by 12 wk.
 
Additional measurements
were made in mice that had been engrafted for 12 wk to
determine whether the numbers and cycling activity of the
human HSCs produced by fetal liver transplants changes af-
ter plateau levels of other types of human hematopoietic
cells are established. The results of limiting dilution second-
ary transplant assays of cells from 12-wk–engrafted primary
mice are shown in the right part of Fig. 2. It can be seen
that there was only a modest (threefold) further increase in
the absolute numbers of human HSCs detectable in the
primary mice between 3 and 12 wk after transplant. Also,
by 12 wk after transplant, an injection of 5-FU into these
mice had no effect (P 
 
  
 
.05) on human HSC detection (1
negative secondary mouse of 16 injected with either con-
trol or 5-FU–treated cells, pooled results from five experi-
ments). In contrast, there were significantly reduced num-
bers of other types of primitive human cells present in the
same cell suspensions from the 5-FU–treated mice (Table
I). These latter findings are consistent with previous
[
 
3
 
H]thymidine studies of the human LTC-ICs and CFCs
regenerated in long-term human cord blood-engrafted
mice that also showed the human LTC-ICs and CFCs to
remain in cycle for at least 12 wk after transplant (25). The
continuing sensitivity of these human fetal liver–derived
progenitors to 5-FU also serves as an internal positive con-
trol for the lack of effect of the 5-FU treatment on the hu-
man HSCs present in the same mice.
 
SDF-1 or TGF-
 
 
 
1
 
 Administration Markedly and Specifically
Enhances the Detection of Proliferating Human HSCs in NOD/
SCID Mice Transplanted with Human Fetal Liver Cells.
 
In a
next series of 11 experiments, we asked whether inhibition
of human HSC cycling in vivo might enhance their detec-
tion and if so, was the effect seen associated with an effect
on human HSC cycling activity. As candidate inhibitors,
TGF-
 
 
 
1
 
 and SDF-1 were chosen. These were administered
as two daily injections (TGF-
 
 
 
1
 
 at 1 
 
 
 
g per injection per
mouse and SDF-1 at 10 
 
 
 
g per injection per mouse) into
mice that had been transplanted 3 wk previously with 10
 
7
 
human fetal liver cells. The doses of TGF-
 
 
 
1
 
 and SDF-1
used were based on previous evidence of their effectiveness
in inhibiting the proliferation (without affecting the num-
ber) of human LTC-ICs and primitive (but not mature) hu-
man CFCs in the marrow of NOD/SCID mice engrafted
with human cord blood HSCs (25, 26). In seven experi-
ments, the human HSC activity in the cells harvested from
the primary mice was then assessed 1 d later by transfer into
secondary NOD/SCID mice. As shown in Fig. 3, both
agents had a similar ability to significantly (P 
 
  
 
.001) block
the proliferation of the human LTC-ICs and primitive (but
not mature) CFCs regenerated in human fetal liver–
engrafted NOD/SCID mice. Note that there was no effect
of either TGF-
 
 
 
1
 
 or SDF-1 on the number of any of these
progenitors detected (in the absence of [
 
3
 
H]thymidine, un-
published data). This indicates that the cytostatic effects seen
on these target cell populations were not complicated by
any evidence of toxicity. Strikingly, as shown in Fig. 4,
there was a dramatic enhancement (
 
 
 
40-fold) in the num-
ber of HSCs detected in the bone marrow of the primary
mice that were injected with either TGF-
 
 
 
1
 
 or SDF-1 as
determined from their quantitation by limiting dilution as-
says in secondary mice. Examples of the markedly different
levels of engraftment obtained in secondary recipients of
similar aliquots of cells harvested from the bone marrow of
untreated as compared with TGF-
 
 
 
1
 
 or SDF-1–treated pri-
mary mice are shown in Fig. 5. Similar results were ob-
tained in a further series of four experiments in which the
cells were not harvested from the primary mice until 3 d af-
ter the injection of either TGF-
 
 
 
1
 
 or SDF-1, demonstrating
that the enhancing effect was durable for at least 3 d.
Figure 2. Changes in the number and 5-FU sensitivity of human HSCs
between 3 and 12 wk after transplantation of human fetal liver cells into
NOD/SCID mice. Marrow cells were removed from both femurs and
tibias of primary mice 2 d after being injected with 5-FU (black bars) or
not (white bars), pooled, and equal proportions transplanted into second-
ary NOD/SCID recipients (4–8 primary mice per group per experiment,
4 experiments, 0.25–0.5 primary mouse marrow equivalents per second-
ary mouse). Secondary mice were analyzed 6 to 8 wk later and human
HSC numbers determined from the numbers of positive and negative sec-
ondary mice obtained. The arrow indicates a maximum value that was
calculated by assuming one of the secondary mice in this group had been
positive. Error bars indicate the range defined by   SEM.
 
Table I.
 
Effect of 5-FU Administration on Human Progenitors in 
the Bone Marrow of NOD/SCID Mice
 
Percentage kill after 5-FU
Time after
transplantation
Primitive
BFU-E
Primitive
CFU-GM LTC-IC
3 wk 78 
 
  
 
4 72 
 
  
 
5 72 
 
  
 
6
12 wk 77 
 
  
 
5 71 
 
  
 
3 72   2
5-FU at 150 mg/kg. Mice killed 2 d after 5-FU administration.1145 Cashman et al.
TGF-  is a well known proliferation inhibitor of many
cell types including primitive human hematopoietic cells
(24, 25, 27, 32). Human HSCs are known to be responsive
to SDF-1 (33, 34), but the potential of SDF-1 to act as an
inhibitor of their cycling status is less well studied, al-
though we recently reported evidence for such a role on
closely related cell types (26). Therefore it was of interest
to determine whether the effect of SDF-1 on HSC detec-
tion was associated with an effect on HSC proliferation in
the same model.
To examine this possibility, the same experimental de-
sign was used but all 3-wk–engrafted primary mice were
injected with SDF-1 and then, before transferring the cells
into secondary recipients, a [3H]thymidine suicide assay
was performed. The similar levels of engraftment obtained
in secondary recipients of either control or [3H]thymidine-
treated cells are shown in Fig. 6. Calculation of the HSC
values derived from these results show that the percentage
of HSCs killed by the exposure to [3H]thymidine was neg-
ligible (6%). These clearly establish that SDF-1 pretreat-
ment of human HSCs proliferating in vivo caused their ar-
rest in Go, as none entered S-phase during a subsequent
period of incubation for 16 h in vitro in the presence of SF,
IL-3, and G-CSF. These findings stand in marked contrast
to the significant reduction in HSC activity obtained when
the primary mice were not first given SDF-1 (see Fig. 1).
In a final series of experiments, we asked whether the in
vivo SDF-1 treatment might have an independent effect on
the ability of noncycling human HSCs to engraft NOD/
SCID mice. Accordingly, additional primary mice that had
been engrafted with human fetal liver cells for 12 wk were
injected with SDF-1 (two daily doses of 10  g/injection/
mouse) or PBS (as a negative control) and the human HSC
activity detectable 1 d later was then compared by trans-
planting equal proportions of bone marrow from the pri-
mary mice into secondary mice. All secondary mice
Figure 3. TGF- 1 and SDF-1 administration in vivo arrests the cycling
of primitive (but not mature) human CFCs and human LTC-ICs regen-
erating in the marrow of primary NOD/SCID recipients of 107 low-den-
sity human fetal liver cells. 18 to 21 d after transplant, primary mice were
given two intraperitoneal injections, 24 h apart, of 1  g of TGF- 1 (gray
bars) or 10  g of SDF-1 (black bars), or an equivalent volume of PBS
(white bars) and 2 d later the marrow cells from both femurs and tibias of
all mice in the same group (6 to 8 per group in each experiment) were
pooled and then exposed (or not) to [3H]thymidine for 16 h in vitro be-
fore plating in assays for human CFCs and LTC-ICs. Values shown are
the mean   SEM of the results obtained from a total of six experiments.
Data marked with asterisks are significantly different from the corre-
sponding control values (P   .001).
Figure 4. In vivo administration of TGF- 1 or SDF-1 enhances the
ability of human HSCs in regenerating primary NOD/SCID mice to en-
graft secondary mice. Equal aliquots of primary mouse marrow cells were
transplanted into secondary mice (.25 primary mouse marrow equivalents
per secondary mouse) and 6 to 8 wk later the number of different types of
human cells in the four hind leg bones of each mouse was determined.
These were used to identify mice as positive or negative for human mul-
tilineage engraftment and thence to provide data for HSC calculations.
Each bar indicates the mean   SEM of the total number of HSCs deter-
mined to be present in the control (gray bar) primary mice or in the pri-
mary mice infected with SDF-1 or TGF- 1 and assessed wither 1 d (black
bars) or 3 d (white bars) after the last infection.
Figure 5. FACS® profiles of the human cells regenerated in the marrow
of secondary NOD/SCID recipients. The proportions of human lym-
phoid (top row) and myeloid (bottom row) cells are shown in the sec-
ondary recipients of marrow from primary NOD/SCID mice injected
with PBS (left profiles), SDF-1 (middle profiles), or TGF-  (right pro-
files). All primary mice were injected with the same innoculum of human
fetal liver cells from one of the experiments depicted in Fig. 4.1146 Effects of SDF-1 and TGF-  on Human Stem Cell Transplantability
showed regeneration of multilineage human hematopoiesis
6 to 8 wk later (i.e., 15 of 15 recipients of control cells and
16 of 16 recipients of cells from SDF-1–treated mice in a
total of four experiments) and, as shown in Fig. 7, for each
type of human cell monitored, there was no difference in
the level of engraftment obtained in the secondary recipi-
ents of control versus SDF-1–treated cells.
Discussion
The ability of intravenously injected human hematopoi-
etic cells to home into the marrow of sublethally irradiated
NOD/SCID mice and initiate multilineage hematopoiesis
in this xenogeneic microenvironment has been instrumen-
tal to the development of an experimental model for char-
acterizing the properties and in vivo behavior of transplant-
able human HSCs. This has included the demonstration in
engrafted primary mice of human cells able to initiate mul-
tilineage hematopoiesis upon transfer to secondary recipi-
ents. Indeed, in some instances, larger numbers of such cells
can be detected in the repopulated primary mice than were
originally injected into them (14). These observations have
suggested that human HSCs also generate progeny HSCs
when they are stimulated to divide and differentiate in the
marrow of the engrafted murine host. However, this type
of experimental design cannot exclude the possibility that
some might be cells with multilineage potential that were
already present in the original innoculum but did not pro-
duce detectable progeny within the first 6–8 wk in the pri-
mary NOD/SCID hosts. Such a possibility is supported by
the recent finding that CD34  human cells with engrafting
ability can be produced in vitro from CD34  cells that do
not, themselves, generate mature progeny in vivo in this
time frame (35, 36) and that, even in NOD/SCID mice,
the human lympho-myelopoiesis seen during the first 3 to
4 wk is largely due to a more mature subset of human re-
populating cells than those whose progeny appear later (17,
37, 38).
Here we provide direct evidence that the initially regen-
erated human HSCs (defined by a 6–8-wk multilineage re-
population read-out in secondary NOD/SCID mice) are
actively dividing cells that have either acquired or retain
the properties of transplantable HSCs. This was demon-
strated using two different strategies that specifically target
Figure 6. In vivo treatment of primary mice with SDF-1
results in similar levels of engraftment in secondary recipi-
ents of either control or [3H]thymidine-treated cells. 18 to
21 d after transplant, human fetal liver–engrafted primary
mice were given two intraperitoneal injections, 24 h apart,
of 10  g of SDF-1 and 2 d later the marrow cells from
both femurs and tibias of all mice in each experiment (7–9
mice per experiment, four experiments) were pooled and
then incubated with [3H]thymidine (filled symbols) or me-
dium (open symbols) for 16 h in vitro. The cells were then
harvested and equal aliquots of each pool injected into sec-
ondary NOD/SCID mice (25–.33 primary mouse marrow
equivalents per secondary mouse). Levels of different types
of human cells detected in the secondary mice were deter-
mined 6–8 wk later.
Figure 7. In vivo administration of SDF-1 does not alter
the ability of quiescent human HSCs in primary NOD/
SCID mice to engraft secondary mice. Primary mice trans-
planted with human fetal liver cells 12 wk previously were
injected on two successive days with 10  g of SDF-1 or an
equal volume of PBS and then killed 1 d later (six animals
per group, four experiments). Equal aliquots from each
group were transplanted into secondary mice (.38 primary
mouse marrow equivalents per secondary mouse) and after
a further 6 to 8 wk the number of different types of human
cells in the four hind leg bones of the secondary recipients
of SDF-1 (filled symbols) or PBS (open symbols) treated
primary marrow cells was determined.1147 Cashman et al.
proliferating cell populations (exposure to high specific ac-
tivity [3H]thymidine in vitro or 5-FU in vivo). Interest-
ingly, we found that this proliferative activity was markedly
down-regulated in the mice 9 wk later, although presum-
ably remaining at a level just sufficient to balance the daily
loss of HSCs into the pool of more differentiated progeni-
tors since the total size of the human HSC compartment
did not decrease. The lack of effect of 5-FU on human
HSCs present in 12–wk–engrafted mice in contrast to the
marked decrease seen in 3-wk–engrafted mice demon-
strates the power of this simple strategy for future assess-
ment of agents/conditions that can alter human HSC cy-
cling in vivo.
Our studies also add to a growing body of evidence that
the number of human HSCs detected after their transplan-
tation into NOD/SCID mice can vary markedly according
to their recent cytokine exposure history (21, 23, 39). Here
we show a dramatic increase in human HSC detection can
be obtained after treatment of engrafted mice with either
SDF-1 or TGF- 1 under certain conditions. The increase
seen is much larger than the two- to threefold effect antici-
pated if previously undetectable S/G2/M-phase HSCs had
simply been forced to accumulate in G1 over a 2 to 3-d pe-
riod. In fact, others have shown that human HSCs already
begin to lose their ability to engraft upon exit from Go into
G1 (21). This indicates that cells with the proliferative and
differentiative potential of HSCs can be greatly underesti-
mated by in vivo assays that depend on the integrity of
their marrow homing efficiency. Conversely, if proliferat-
ing HSCs are forced to reenter Go, as indicated here by the
acquired [3H]thymidine insensitivity of HSCs from mice
treated with SDF-1 3 wk after transplant, then large in-
creases in HSC detection could be obtained. Our finding
that SDF-1 treatment of already quiescent HSCs (in 12-
wk–engrafted mice) has no effect on their transplantability
provides strong support for the concept that the effect seen
on proliferating HSCs is related to the ability of SDF-1 to
force their return to a Go state. More detailed characteriza-
tion of the mechanism(s) responsible will clearly command
attention in future studies. Involvement of various mole-
cules implicated in HSC homing, including CXCR4, the
receptor for SDF-1 and  1integrins (33, 40–43) are obvious
candidates for investigation. However, regardless of the
mechanisms underlying the dramatic effects of SDF-1 and
TGF- 1 on proliferating human HSCs, these findings un-
derscore the importance of cycling status on the ability of
these cells to be detected or used effectively for transplanta-
tion applications. These issues will be particularly relevant
to the future optimization of protocols for the clinical
transplantation of HSCs to be cultured ex vivo or procured
from patients that have been given treatments that activate
as well as mobilize HSCs.
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